BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT) is a clinical stage immuno-oncology company that is d...
10/09/2025

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT) is a clinical stage immuno-oncology company that is developing novel to transform cancer care. https://bit.ly/3TF7Jn0

In BriaCell’s Phase 2 study of Bria-IMT™, Overall Survival of patients were comparable to or better than that of Trode...
10/07/2025

In BriaCell’s Phase 2 study of Bria-IMT™, Overall Survival of patients were comparable to or better than that of Trodelvy in similar patients.

Responses were observed in Central Nervous System (CNS) mets, Antibody-drug conjugates (ADCs) resistant and checkpoint inhibitor (CPI) resistant ( ) patients. https://bit.ly/3cNVi8a

10/03/2025

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. For presentation details, please visit: https://bit.ly/4pQzGIM

October marks .According to the American Cancer Society, 316,950 women and 2,800 men are expected to be diagnosed with ...
10/01/2025

October marks .

According to the American Cancer Society, 316,950 women and 2,800 men are expected to be diagnosed with invasive breast cancer in 2025 in the U.S. alone. For more information, please visit: https://briacell.com/about-briacell/

09/04/2025

Dr. William V. Williams, BriaCell’s President and CEO, discusses the Company's recent publication detailing the mechanism of action of its Bria-OTS+ : https://bit.ly/41RcsI8

09/02/2025

“This publication validates the core design principle behind Bria-OTS+: partial HLA matching enables effective tumor-antigen presentation, while planned HLA mismatching drives robust CD4⁺ helper responses,” noted Miguel Lopez-Lago, PhD, BriaCell’s CSO. To learn more about the publication, visit: https://bit.ly/41RcsI8

08/28/2025

Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer, highlighted that the recent NCI grant represents another important milestone in advancing cancer care with Bria-OTS+™. https://bit.ly/47e4zQy

08/27/2025

“This prestigious award will help expedite the clinical development of Bria-PROS+ and is significant validation of our next generation novel personalized immunotherapy approach,” added Dr. William V. Williams, BriaCell’s President and CEO. Learn more: https://bit.ly/47e4zQy

08/26/2025

Jay A. Berzofsky, MD, PhD, Senior Investigator of NCI and coauthor of the publication, highlights new data from BriaCell and the NCI, that supports anti-tumor effects of BriaCell's Bria-OTS+ platform. Learn more: https://bit.ly/41RcsI8

08/26/2025

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) today announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy. This research conducted in collaboration with the National Cancer Institute (NCI), the US federal government’s principal agency for cancer research and training, has been published at JCI Insight, a highly rated peer-reviewed journal dedicated to advancing biomedical research from preclinical discovery through to clinical development. Find details: https://bit.ly/41RcsI8

08/25/2025

“We are grateful to the NCI for recognizing the urgency for this unmet medical need and supporting BriaCell’s breakthrough immunotherapy,"" said Dr. William Oh, MD, Director of Precision Medicine, Yale Cancer Center, and Principal Investigator on the upcoming Phase 1/2a clinical study of Bria-PROS+ in advanced prostate cancer. Discover more: https://bit.ly/47e4zQy

08/25/2025

The non-dilutive grant from NCI, titled “Phase 1/2a clinical trial to investigate Bria-PROS+™ in patients with metastatic prostate cancer”, will be used to complete manufacturing of Bria-PROS+ and to fund BriaCell's upcoming Phase 1/2a study in patients with advanced prostate cancer. https://bit.ly/47e4zQy

Address

2929 Arch Street, 3rd Floor
Philadelphia, PA
19104

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

BriaCell Therapeutics

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell based product candidate derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.